Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).
Kimizuka K, Inoue K, E Nagai S, Saito T, Nakano S, Futsuhara K, Yamada H, Kaneko S, Sakurai T, Hata S, Kurosumi M. Kimizuka K, et al. J Nippon Med Sch. 2019;86(3):165-171. doi: 10.1272/jnms.JNMS.2019_86-305. J Nippon Med Sch. 2019. PMID: 31292328 Free article.
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.
Inoue K, Nagai SE, Saito T, Sakurai T, Kimizuka K, Yamada H, Kuroda T, Hata S, Yamazaki Y, Kojima M, Futsuhara K; SBCCSG-14 investigators. Inoue K, et al. Among authors: kimizuka k. Invest New Drugs. 2020 Feb;38(1):140-147. doi: 10.1007/s10637-019-00829-w. Epub 2019 Jul 10. Invest New Drugs. 2020. PMID: 31289984 Free PMC article.
Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
Inoue K, Ninomiya J, Saito T, Okubo K, Nakakuma T, Yamada H, Kimizuka K, Higuchi T; SBCCSG-36 investigators. Inoue K, et al. Among authors: kimizuka k. Invest New Drugs. 2019 Jun;37(3):592-593. doi: 10.1007/s10637-019-00773-9. Invest New Drugs. 2019. PMID: 31025237 Free PMC article.
Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
Inoue K, Ninomiya J, Saito T, Okubo K, Nakakuma T, Yamada H, Kimizuka K, Higuchi T; SBCCSG-36 investigators. Inoue K, et al. Among authors: kimizuka k. Invest New Drugs. 2019 Jun;37(3):538-547. doi: 10.1007/s10637-019-00755-x. Epub 2019 Mar 8. Invest New Drugs. 2019. PMID: 30848403 Free PMC article. Clinical Trial.
Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.
Inoue K, Ninomiya J, Saito T, Kimizuka K, Kurosumi M. Inoue K, et al. Among authors: kimizuka k. BMC Cancer. 2018 Jun 20;18(1):671. doi: 10.1186/s12885-018-4556-6. BMC Cancer. 2018. PMID: 29925345 Free PMC article. Clinical Trial.
A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer.
Yamada H, Inoue K, Nagai SE, Nakai M, Arisawa F, Ueda H, Saito T, Ninomiya J, Kuroda T, Sakurai T, Kodama H, Kimizuka K, Hata S, Kai T, Kurosumi M; SBCCSG investigators. Yamada H, et al. Among authors: kimizuka k. J Nippon Med Sch. 2017;84(5):215-223. doi: 10.1272/jnms.84.215. J Nippon Med Sch. 2017. PMID: 29142182 Free article.
[Surgical Resection of Solitary Brain Metastasis from Breast Cancer].
Kimizuka K, Miyake H, Sugiyama J, Ogura M, Kamisada N, Ohhara M, Kang W, Katoh R, Satoh H, Yokose N, Satoh S, Fukushima M. Kimizuka K, et al. Gan To Kagaku Ryoho. 2016 Nov;43(12):1464-1466. Gan To Kagaku Ryoho. 2016. PMID: 28133024 Japanese.
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K, Saito T, Okubo K, Kimizuka K, Yamada H, Sakurai T, Ishizuna K, Hata S, Kai T, Kurosumi M. Inoue K, et al. Among authors: kimizuka k. Breast Cancer Res Treat. 2016 Jun;157(2):295-305. doi: 10.1007/s10549-016-3808-x. Epub 2016 Apr 28. Breast Cancer Res Treat. 2016. PMID: 27125669 Free PMC article. Clinical Trial.
34 results